Skip to navigation Skip to content

Progressive fibrosing interstitial lung disease (PF-ILD) Program in Pharmaceutical Benefits Scheme 012-22042647

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised nintedanib for patients with progressive fibrosing interstitial lung disease (PF-ILD).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings. Contact a Local Peer Support (LPS) if unsure of how to action an application.

Progressive fibrosing interstitial lung (PF-ILD) disease quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB332 form

Written

Electronic

S85:

nintedanib

No

OPA

Must be treated by, or in consultation with a:

  • respiratory physician
  • specialist physician

Yes

Continuing

Telephone

Electronic

S85:

nintedanib

 

No

OPA

Must be treated by, or in consultation with a:

  • respiratory physician
  • specialist physician

Yes